Hereditary angioedema (HAE) is a rare genetic syndrome caused by a deficiency in functional C1 inhibitor that results in recurrent episodes of nonpruritic swelling of the hands, feet, arms, legs, ...

AAEM statements are not to be construed as dictating an exclusive course of action nor are they intended to replace the medical judgment of healthcare professionals. The unique circumstances of ...

Optimal care for female and pediatric patients with hereditary angioedema (HAE) requires consideration of several population-specific issues. For women, these include menstruation, contraception, ...

Management of hereditary angioedema due to C1 inhibitor deficiency has evolved. During the past 10 years, those affected have progressed from underrecognized disability and premature death, through ...

Hereditary angioedema (HAE) is a genetic syndrome caused by a functional deficit in complement C1 inhibitor that results in recurrent episodes of nonpruritic swelling of the hands, feet, arms, legs, ...

Hereditary angioedema (HAE) is a rare genetic disorder characterised by recurrent, non-itchy swelling of the skin, mucous membranes and submucosal tissues, with potentially life-threatening airway ...

Hereditary angioedema (HAE) can cause attacks triggered by stress. People with the condition may experience a cycle of stress, concerned about when the next attack might appear, which may trigger more ...

In addition to the pharmacotherapeutic options discussed above, auxiliary strategies like trigger avoidance and attack preparedness are two important hereditary angioedema (HAE) management approaches.

Pharvaris, a biopharmaceutical company focusing on innovative oral treatments for bradykinin-mediated diseases like hereditary angioedema (HAE), recently shared data from the European Academy of ...

Angioedema, a type of swelling that affects the skin and tissues of the body, commonly affects the lips. Angioedema is a type of swelling that affects the deep tissues of the skin and other systems.

–Attack progression halted in median 19.8 minutes after treatment with sebetralstat in both KONFIDENT and KONFIDENT-S trials– –Sebetralstat data demonstrated rapid relief and resolution of severe HAE ...